AlloVir/Baylor, Soligenix/Hawaii and CEL-SCI/Georgia ink coronavirus collaborations, but deal-making continues in other areas as well, including Asklepios/UNC teaming on a gene therapy for Angelman syndrome and DeMelle licensing a targeted pancreatic cancer drug from Moffitt, among others.

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

Bayer will collaborate with start-up Hope Medicine to develop antibody therapies targeting the PRL receptor. WARF and Sanford Burnham Prebys partner on translational research.

Partnership will test Mustang’s MB-101 with a second-generation oncolytic HSV-1 virus for potential in treating brain cancer. Canadian biotech launched by CCAB to fight the same cancer.